Developing Disruptive Therapeutics for the Treatment of  Patients with Urgent Unmet Medical Needs

Pancreatic Cancer

Pancreatic ductal adenocarcinoma is characterized by elevated levels of polyamines, a natural component for growth of all mammalian cells. Panbela is studying the effect of SBP-101, a polyamine metabolic inhibitor and one of Panbela’s molecules in development, in disrupting cancer cell metabolism when added to standard of care treatment regimens for pancreatic cancer.

Clinical Trials

Panbela Therapeutics, Inc. is currently conducting a Phase 1a/1b combination of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma at sites in the United States and Australia.

Panbela Therapeutics Inc. formerly known as Sun BioPharma, Inc. is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd.